Streetbeat News

Price Targets

CMPS

EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Compass Pathways (NASDAQ:CMPS) and maintained a price target of $38.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:48 am

ZWS

Keybanc analyst David Tarantino maintains an Overweight rating on Zurn Elkay Water (NYSE:ZWS) and raises the price target from $28 to $31.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:47 am

WCC

Keybanc analyst Ken Newman has maintained an Overweight rating on WESCO Intl (NYSE:WCC) and raised the price target from $175 to $210.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:46 am

URI

Keybanc analyst Ken Newman has maintained an Overweight rating on United Rentals (NYSE:URI) and raised the price target from $475 to $520.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:45 am

SNPS

Keybanc analyst Jason Celino maintains an Overweight rating on Synopsys (NASDAQ:SNPS) and raises the price target from $467 to $500.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:43 am

RXRX

Keybanc analyst Scott Schoenhaus maintains an Overweight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and raises the price target from $12 to $15.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:42 am

PH

Keybanc analyst Jeffrey Hammond maintains an Overweight rating on Parker Hannifin (NYSE:PH) and raises the price target from $390 to $450.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:41 am

OMCL

Keybanc analyst Scott Schoenhaus maintains an Overweight rating on Omnicell (NASDAQ:OMCL) and raises the price target from $70 to $80.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:40 am

ITT

Keybanc analyst Jeffrey Hammond maintains an Overweight rating on ITT (NYSE:ITT) and raises the price target from $100 to $110.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:39 am

LPTX

Raymond James analyst Steven Seedhouse maintains an Outperform rating on Leap Therapeutics (NASDAQ:LPTX) and raises the price target from $17 to $18.5.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:38 am